このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NRx Pharmaceuticals マネジメント

マネジメント基準チェック /34

NRx Pharmaceuticals'の CEO はSteve Willardで、 Jul2022年に任命され、の在任期間は 2.08年です。の年間総報酬は$ 500.00Kで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.98%を直接所有しており、その価値は$ 240.45K 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と2.1年です。

主要情報

Steve Willard

最高経営責任者

US$500.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	2.2yrs
CEOの所有権	1.0%
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	1.5yrs

経営陣の近況

Recent updates

CEO報酬分析

NRx Pharmaceuticals の収益と比較して、Steve Willard の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	US$500k	US$500k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$234k	-US$40m

報酬と市場: Steveの総報酬 ($USD 500.00K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Steveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Steve Willard (63 yo)

2.2yrs

在職期間

US$500,000

報酬

Mr. Stephen H. Willard, also known as Steve, Esq. serves as Acting Corporate Secretary at NRx Pharmaceuticals, Inc. He serves as Chief Executive Officer and Director at NRx Pharmaceuticals, Inc. since July...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.6m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 183.7k
Richard Narido	CFO & Treasurer	less than a year	US$298.02k	0% $ 0
Riccardo Panicucci	Chief Manufacturing & Technology Officer	3.7yrs	US$240.00k	データなし
Suzanne Messere	Investor Relations	no data	データなし	データなし
Philip Lavin	Chief Methodologist	no data	データなし	データなし
Matthew Duffy	Chief Business Officer	1.5yrs	データなし	データなし

2.2yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: NRXPの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.6m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 183.7k
Chaim Hurvitz	Independent Director	3.3yrs	US$52.50k	2.07% $ 387.6k
Patrick Flynn	Independent Director	3.3yrs	US$67.50k	0.55% $ 103.3k
Janet Rehnquist	Independent Director	less than a year	データなし	データなし
Dennis McBride	Independent Director	less than a year	データなし	データなし

1.5yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: NRXPの取締役会は経験豊富ではない ( 1.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

NRx Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

Recent updates

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals Demonstrates Compliance with the Nasdaq Bid Price Requirement in Listing Rule 5550(a)(2)

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

New major risk - Share price stability

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

Price target increased by 7.1% to US$3.75

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

New major risk - Financial position

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

Co-Founder recently bought US$64k worth of stock

New major risk - Share price stability

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million.

Price target increased by 7.7% to US$3.50

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

CEO & Director recently bought US$59k worth of stock

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Independent Director recently bought US$515k worth of stock

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

マネジメント基準チェック /34